Regulators affirm their stance on current photobiomodulation dosage and exposure guidelines, ensuring ongoing post-market surveillance for biphasic inhibition in clinical data. Recent analyses indicate no decline in efficacy or tissue inhibition at higher irradiances, solidifying confidence in the treatment's safe application. As photobiomodulation therapy continues to demonstrate significant benefits in tissue repair and metabolic health, these findings bolster its adoption across diverse clinical settings.